A parathyroid hormone-related peptide (PTHrP) test is mainly used to investigate certain cases of unexplained high blood calcium, especially when cancer-related hypercalcemia is suspected. PTHrP can be produced by tumors and can act on many of the same receptors as parathyroid hormone (PTH), causing calcium to rise while the body’s own PTH is suppressed. This pattern is called humoral hypercalcemia of malignancy. A high PTHrP result can strongly support that mechanism, but it does not identify the cancer by itself and not all cancer-related hypercalcemia is caused by PTHrP. Kidney function, assay type, pregnancy or lactation, and several uncommon noncancerous conditions can also affect interpretation. The result is therefore read together with total or ionized calcium, albumin, PTH, kidney function, vitamin D metabolites, symptoms, medication history, and the clinical picture. Severe hypercalcemia can be a medical emergency, so the immediate calcium level and symptoms often matter more urgently than the tumor-marker result.
- PTHrP testing is primarily used to investigate PTH-independent hypercalcemia, especially possible humoral hypercalcemia of malignancy.
- High calcium with low or suppressed PTH is a common pattern that prompts consideration of PTHrP testing.
- An elevated PTHrP supports a cancer-related mechanism but is not proof of a particular tumor or cancer stage.
- Advanced kidney disease can cause misleading elevation of some C-terminal PTHrP assays.
- Severe hypercalcemia with confusion, dehydration, vomiting, marked weakness, or heart-rhythm symptoms needs urgent medical assessment.
Table of Contents
- What PTHrP is and why it is tested
- How PTH, calcium, and PTHrP fit together
- What a high PTHrP level means
- Cancers associated with PTHrP-related hypercalcemia
- Noncancer causes, kidney disease, and assay limitations
- Hypercalcemia symptoms and when it is urgent
- Testing, treatment monitoring, and follow-up
What PTHrP is and why it is tested
PTHrP is a protein made in many normal tissues, where it has local roles in development and cell function. It shares part of its structure with parathyroid hormone and can activate the same PTH/PTHrP receptor. When a tumor releases large amounts of PTHrP into the circulation, the peptide can produce hormone-like effects throughout the body.
The best-known effect is an increase in blood calcium. PTHrP stimulates processes that release calcium from bone and increase calcium conservation by the kidneys. As calcium rises, the parathyroid glands normally reduce their own PTH production. That is why humoral hypercalcemia of malignancy typically produces the combination of high calcium, low PTH, and elevated PTHrP.
PTHrP is not a general cancer screening test. It is usually ordered after hypercalcemia has already been confirmed and the initial evaluation suggests that the high calcium is not being driven by ordinary primary hyperparathyroidism.
Before PTHrP is measured, clinicians commonly confirm the calcium abnormality. Total calcium is affected by albumin, so a corrected value or ionized calcium may be useful when albumin is abnormal or the result is uncertain. PTH is then a key branching test. If PTH is high or inappropriately normal despite hypercalcemia, primary hyperparathyroidism or another PTH-mediated cause becomes more likely. If PTH is suppressed, malignancy and several other causes move higher on the list.
The PTHrP result is therefore part of a diagnostic pathway rather than a stand-alone tumor marker. It helps answer a specific question: is excess PTHrP a plausible reason this patient has PTH-independent hypercalcemia?
How PTH, calcium, and PTHrP fit together
Interpreting PTHrP begins with the calcium and PTH pattern.
High calcium with high or inappropriately normal PTH usually points away from humoral hypercalcemia of malignancy. In a person whose calcium is clearly elevated, normal parathyroid glands should reduce PTH. A PTH value that fails to suppress therefore suggests a PTH-driven process, most commonly primary hyperparathyroidism, although other diagnoses are possible.
High calcium with low PTH is the classic setting for considering malignancy-related hypercalcemia. At this point, PTHrP can help identify one mechanism. Other tests may include creatinine, phosphate, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, serum or urine protein studies, and targeted imaging or hematologic evaluation based on the clinical picture.
High calcium, low PTH, and high PTHrP strongly supports humoral hypercalcemia of malignancy when the assay result is reliable and the clinical setting fits. Tumor-produced PTHrP acts systemically, causing calcium elevation without the parathyroid glands being the source of the hormone signal.
High calcium, low PTH, and normal PTHrP does not exclude cancer. Malignancy can cause hypercalcemia through direct bone destruction, increased production of active vitamin D, secretion of other mediators, or mixed mechanisms. Multiple myeloma and cancers with extensive bone metastases, for example, can raise calcium without a high circulating PTHrP.
The pattern also explains why measuring PTHrP in someone whose PTH is clearly elevated may add little. Laboratory testing is most useful when each result narrows the differential diagnosis.
What a high PTHrP level means
A high PTHrP result means the concentration measured by that laboratory exceeds its validated reference interval. It does not have one universal cutoff because laboratories use different antibody targets, assay designs, units, and reference populations.
For example, Mayo Clinic Laboratories currently reports an upper reference value for its plasma assay in picomoles per liter. Other laboratories may use different methods and ranges. Results from two different PTHrP assays should not be assumed to be directly comparable.
When hypercalcemia is present and PTH is suppressed, a clearly elevated PTHrP substantially increases suspicion for humoral hypercalcemia of malignancy. This is especially true when a patient has a known cancer type associated with PTHrP production or has symptoms or imaging findings concerning for malignancy.
The magnitude of PTHrP does not provide a precise cancer stage. A high value cannot tell where a tumor originated, whether it has metastasized, or what treatment will work. It also should not replace tissue diagnosis when a new cancer is being investigated.
PTHrP may fall when effective cancer therapy reduces the tumor’s secretory activity, and serial measurements can sometimes support treatment assessment. In practice, however, calcium concentration, symptoms, kidney function, hydration, and the status of the underlying cancer are usually more important for day-to-day management.
A borderline elevation deserves particular care. Assay interference, reduced renal clearance of certain PTHrP fragments, and nonmalignant physiological states can complicate interpretation. If the result does not fit the clinical picture, clinicians may confirm which type of assay was used or repeat testing with an appropriate method.
Cancers associated with PTHrP-related hypercalcemia
Humoral hypercalcemia of malignancy is classically associated with tumors that secrete PTHrP. Squamous cell carcinomas are prominent examples, including squamous cancers of the lung, head and neck, esophagus, cervix, and other sites. PTHrP-mediated hypercalcemia can also occur with renal, bladder, breast, ovarian, and other solid tumors.
The association is not absolute. A person with one of these cancers may never develop hypercalcemia, and a person with hypercalcemia from cancer may have a different mechanism. The cancer type therefore guides probability but does not determine the laboratory pattern.
PTHrP-related hypercalcemia often occurs in advanced malignancy, although timing varies. It may occasionally be the first clue that leads to a cancer diagnosis. When a patient without known malignancy has significant PTH-independent hypercalcemia and elevated PTHrP, the clinician usually looks for an underlying tumor using the history, physical examination, age-appropriate cancer evaluation, imaging, and other targeted tests.
Malignancy-related hypercalcemia can also involve more than one mechanism at once. A tumor may secrete PTHrP and also involve bone. This matters because the laboratory result explains part of the calcium disturbance but does not describe the entire cancer burden.
High PTHrP is sometimes described as a “tumor marker,” but its clinical role is narrower than markers used for routine cancer follow-up. It is primarily a mechanistic marker of hypercalcemia. The correct question is not simply whether PTHrP is high, but whether the result explains the patient’s calcium abnormality in the context of suppressed PTH and a plausible underlying disease.
Noncancer causes, kidney disease, and assay limitations
PTHrP can be elevated in circumstances other than cancer. Pregnancy and lactation are important physiological examples because PTHrP has roles in the placenta and breast. Several uncommon inflammatory, endocrine, or benign conditions have also been associated with measurable elevations.
One of the most important laboratory pitfalls occurs in advanced kidney disease. PTHrP exists as different fragments. Some laboratories historically measured C-terminal PTHrP fragments, which can accumulate when kidney function is poor. A patient with chronic kidney disease may therefore have an elevated C-terminal PTHrP result even without humoral hypercalcemia of malignancy.
A 2023 report highlighted this problem and recommended attention to assay selection in advanced kidney disease. When malignancy-related hypercalcemia is being evaluated in a patient with severe renal impairment, an N-terminal PTHrP assay may be more clinically appropriate because C-terminal fragments can be misleadingly high.
This is a good example of why a test name alone is not enough. Clinicians may need to know which fragment the laboratory measures, particularly when a result appears inconsistent with the rest of the evaluation.
Kidney disease also complicates the hypercalcemia workup in other ways. Renal function influences phosphate, vitamin D metabolism, hydration, and the safety of some treatments. These factors must be considered separately from the PTHrP concentration.
Biotin and other forms of assay interference can affect certain immunoassays, depending on the platform. Patients should provide a complete medication and supplement list. They should not stop prescribed drugs or supplements solely because of an internet recommendation; the laboratory or treating clinician can provide test-specific preparation instructions.
Hypercalcemia symptoms and when it is urgent
The urgency of a PTHrP evaluation is usually determined by the calcium level and the patient’s condition, not by the PTHrP number itself.
Mild hypercalcemia may cause no symptoms. As calcium rises, people can develop thirst, frequent urination, dehydration, constipation, nausea, reduced appetite, fatigue, muscle weakness, or difficulty concentrating. More severe hypercalcemia can cause vomiting, marked dehydration, confusion, drowsiness, kidney injury, abnormal heart rhythms, and, in extreme cases, coma.
Cancer-associated hypercalcemia can worsen rapidly because dehydration and kidney dysfunction reinforce the calcium rise. A person with known cancer and new confusion, profound weakness, repeated vomiting, inability to maintain fluids, reduced consciousness, or significant heart symptoms needs urgent medical evaluation.
Treatment of hypercalcemia of malignancy may include intravenous fluids when appropriate, antiresorptive medication such as an intravenous bisphosphonate or denosumab, calcitonin for a rapid but short-lived effect in severe cases, and treatment directed at the underlying cancer. The Endocrine Society guideline emphasizes antiresorptive therapy for adults with hypercalcemia of malignancy and provides specific recommendations based on severity and prior response.
The cause still matters even during urgent treatment. Hypercalcemia from excess active vitamin D, for example, may call for different adjunctive therapy than PTHrP-mediated disease. PTHrP testing can help clarify the mechanism while clinicians stabilize the calcium.
Testing, treatment monitoring, and follow-up
PTHrP is usually measured in plasma, and specimen handling can be strict. The correct collection tube, processing time, temperature, and transport method depend on the laboratory. Because the peptide can be unstable, a poorly handled sample may compromise the result. The ordering laboratory’s instructions should be followed exactly.
No universal fasting rule applies to every PTHrP assay. More important is accurate documentation of calcium, albumin or ionized calcium, PTH, creatinine, symptoms, medications, and relevant cancer history.
When PTHrP is elevated in a patient with PTH-independent hypercalcemia, follow-up is directed at both the immediate metabolic problem and its cause. The clinician may order imaging or biopsy if cancer has not yet been diagnosed. If malignancy is already known, the result may help attribute the calcium disturbance to tumor secretion and guide the broader management plan.
During treatment, calcium is monitored far more frequently than PTHrP because the clinical risk comes from hypercalcemia itself. Kidney function, phosphate, magnesium, hydration status, and symptoms may also require close monitoring. PTHrP can be repeated selectively if it would help assess whether the secretory process is improving or recurring.
A falling PTHrP alongside a sustained normal calcium can be reassuring, but neither result alone proves that cancer is controlled. Conversely, recurrent hypercalcemia can appear before a repeat PTHrP result is available and should be treated on its own clinical urgency.
For patients with kidney failure or an unexpected PTHrP elevation, asking the laboratory whether the assay targets the N-terminal or C-terminal region can prevent a serious diagnostic error. The safest interpretation always links the assay method to the biochemical pattern and the patient’s overall condition.
The calcium result itself also needs careful interpretation. Total serum calcium can appear low or high when albumin is abnormal because much of circulating calcium is protein-bound. In patients with cancer, malnutrition, inflammation, liver disease, or critical illness can make albumin unreliable. Measuring ionized calcium can clarify the biologically active calcium concentration when the corrected total calcium is uncertain.
Phosphate can provide another clue. PTH and PTHrP both tend to promote renal phosphate loss, so phosphate may be low in PTHrP-mediated hypercalcemia. This pattern is supportive rather than diagnostic because nutrition, kidney function, medications, and other endocrine disorders also affect phosphate. Likewise, 1,25-dihydroxyvitamin D may be useful when lymphoma or granulomatous disease is suspected, while serum and urine protein studies may be appropriate when multiple myeloma is a concern.
The timing of PTHrP testing relative to treatment matters. Intravenous fluids, calcitonin, bisphosphonates, or denosumab can lower calcium without immediately eliminating tumor PTHrP production. A normalizing calcium level therefore does not necessarily mean the underlying secretory mechanism has stopped. Conversely, effective anticancer therapy may reduce PTHrP before a large change in tumor size is visible.
For long-term follow-up, recurrent high calcium is usually more clinically important than a small isolated change in PTHrP. Patients with a history of malignancy-associated hypercalcemia may be advised to report increasing thirst, frequent urination, constipation, nausea, or new cognitive changes early. Recognizing recurrence before severe dehydration develops can make treatment safer and reduce the risk of kidney injury.
A normal PTHrP result should therefore be interpreted as “this mechanism was not demonstrated,” not “cancer was excluded.” When PTH remains suppressed, clinicians still consider other PTH-independent causes such as vitamin D excess, lymphoma-related calcitriol production, extensive bone disease, medications, endocrine disorders, and prolonged immobilization. The rest of the laboratory pattern directs which of these possibilities deserves testing.
Patients who have already experienced malignancy-related hypercalcemia also benefit from a clear recurrence plan. That may include periodic calcium checks during oncology visits and faster testing if symptoms return. Because dehydration can amplify calcium elevation, early recognition and fluid assessment can prevent a mild biochemical recurrence from becoming a severe metabolic emergency.
References
– Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline 2023 (clinical practice guideline) – Treatment of hypercalcaemia of malignancy in adults 2023 (guideline summary) – PTH-Related Protein Assays in Advanced Kidney Disease: Implications for Evaluation of Hypercalcemia 2023 (clinical review) – Hypercalcemia in Cancer: Causes, Effects, and Treatment Strategies 2024 (review) – Development of a PTHrP chemiluminescent immunoassay to assess humoral hypercalcemia of malignancy 2022 (assay study) – PTHRP – Overview: Parathyroid Hormone-Related Peptide, Plasma 2026 (laboratory reference)
Disclaimer
This article is for general education and is not a substitute for medical evaluation of hypercalcemia or suspected cancer. PTHrP reference intervals and assay targets differ among laboratories, and advanced kidney disease can cause misleading results with some methods. Severe or symptomatic hypercalcemia can be an emergency and requires prompt clinical assessment regardless of the PTHrP value.
